Elena Moreno-Olmedo: Glad to share our 10-year results at ASTRO 2023.
Quoting Elena Moreno-Olmedo, RadioOncology Clinical Research Fellow at University of Oxford, on X/Twitter:
“Glad to share our 10y results at ASTRO 2023.
Looking for the biological benefit of ultra hypo fractionation, safety and comfort of the patient and cost-effectiveness of the process, this prospective study was initiated in 2010.
1st endpoints: validation inmobilization system and dose schedule.
2nd: potential predictive risk factors and relationship PSA nadir and survival.
120 pts. LR+IR. 101 GS 6. 90% cT1c-T2a (mpMRI).
US-guided transperineal implant, rigid catheters, sutured fixed template.
Toxicity profile:
Uni and multivariate analysis found significant factors, associated with/ any grade of acute GU tox: IPSS, prostate vol, V100, V150, V200, and D10% urethra.
10y survival outcomes below.
Future directions? Let’s extrapolate to SABR.”
For more information click here.
Source: Elena Moreno-Olmedo/Twitter.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023